158 related articles for article (PubMed ID: 29019439)
1. Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
Vitagliano O; Trastulli F; Cacace F; Leone S; Memoli M; Scalia G; Notarangelo M; Mainolfi CG; De Renzo A; Pane F
Leuk Lymphoma; 2018 Jul; 59(7):1734-1737. PubMed ID: 29019439
[No Abstract] [Full Text] [Related]
2. Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
Tucker DL; Naylor G; Kruger A; Hamilton MS; Follows G; Rule SA
Br J Haematol; 2017 Jul; 178(2):327-329. PubMed ID: 27197509
[No Abstract] [Full Text] [Related]
3. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Shibayama H; Choi I; Hatake K; Uchida T; Nishikori M; Kinoshita T; Matsuno Y; Nishikawa T; Takahara S; Tobinai K
Cancer Sci; 2016 Dec; 107(12):1785-1790. PubMed ID: 27616553
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.
Landsburg DJ; Hughes ME; Koike A; Bond D; Maddocks KJ; Guo L; Winter AM; Hill BT; Ondrejka SL; Hsi ED; Nasta SD; Svoboda J; Schuster SJ; Bogusz AM
Blood Adv; 2019 Jan; 3(2):132-135. PubMed ID: 30651281
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
Gordon MJ; Raess PW; Young K; Spurgeon SEF; Danilov AV
Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
[No Abstract] [Full Text] [Related]
7. Successful Treatment of Chronic Lymphocytic Leukemia Multifocal Central Nervous System Involvement with Ibrutinib.
Christoforidou A; Kapsas G; Bezirgiannidou Z; Papamichos S; Kotsianidis Ι
Turk J Haematol; 2018 May; 35(2):147-149. PubMed ID: 29391330
[No Abstract] [Full Text] [Related]
8. Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition.
Jani P; Vissing MB; Ahmed S; Sluzevich JC; Aulakh S; Alegria V; Ailawadhi M; Chanan-Khan A; Ailawadhi S
J Oncol Pract; 2018 Jun; 14(6):387-388. PubMed ID: 29558252
[No Abstract] [Full Text] [Related]
9. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.
Mason C; Savona S; Rini JN; Castillo JJ; Xu L; Hunter ZR; Treon SP; Allen SL
Br J Haematol; 2017 Oct; 179(2):339-341. PubMed ID: 27409073
[No Abstract] [Full Text] [Related]
10. Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Kaur V; Swami A
J Oncol Pharm Pract; 2017 Apr; 23(3):235-239. PubMed ID: 26970573
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib is Effective in Refractory Type II Cryoglobulinemia.
Barot SV; Lee SS; Patel BJ; Valent JN
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):e629-e632. PubMed ID: 31585822
[No Abstract] [Full Text] [Related]
12. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma.
Furtado M; Wang ML; Munneke B; McGreivy J; Beaupre DM; Rule S
Br J Haematol; 2015 Jul; 170(1):131-4. PubMed ID: 25559624
[No Abstract] [Full Text] [Related]
14. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
[No Abstract] [Full Text] [Related]
15. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
[No Abstract] [Full Text] [Related]
16. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
17. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
18. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
19. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
20. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
